Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cardiac Water and Fluoromethane Cardiac PET

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00205127
First received: September 12, 2005
Last updated: August 28, 2012
Last verified: August 2012
  Purpose

In this study we are looking at the blood flow to the heart using two different chemical tags or tracers that give off a low level of radiation. The tracers used in this study are called O15-water and F17-fluoromethane. These tracers mix with the blood and will move through the body. The researchers will use positron emission tomography (PET scans)to track the tracers as they moe through the heart and chest.


Condition Intervention
Healthy Volunteers
Procedure: Cardiac PET imaging- rest and pharmacological stress

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Comparison of Cardiac Perfusion by O15-water and F17-fluoromethane PET

Resource links provided by NLM:


Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • -- implement myocardial perfusion quantification for O15-labeled water at rest and with pharmacologic stress, [ Time Frame: assess at time of PET scan ] [ Designated as safety issue: No ]
  • -- determine the biodistribution of fluoromethane in the thorax to see if it is usable for a cardiac perfusion tracer, [ Time Frame: assess at time of PET Scan ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • --develop initial methods for quantification of myocardial perfusion if applicable for labeled fluoromethane. [ Time Frame: assess at time of PET scan ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2004
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1. Age 18 to 40 years old 2. Willing to provide written informed consent

Exclusion Criteria:

  • 1. A history of CAD 2. A history of active bronchospasm or asthma on theophylline bronchodilators 3. A history of any cardiac risk factors including: HTN, Diabetes, Hyperlipidemia, Smoking, and premature CAD in immediate family member 4. A history of liver disease or other significant disease 5. Females who are pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00205127

Locations
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Investigators
Principal Investigator: Charles K Stone, MD Univeristy of Wisconsin
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00205127     History of Changes
Other Study ID Numbers: 2003-241
Study First Received: September 12, 2005
Last Updated: August 28, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Wisconsin, Madison:
Cardiac PET imaging
Radiopharmaceutical tracers

ClinicalTrials.gov processed this record on November 25, 2014